5-7 December 2017

London, UK

Register here

Poster Session

Extract More Value from Predictable Preclinical Data to Enhance Translational Decision Making

With huge investments in oncology drug development, the overall sustainability of high clinical failure rates remains low. Today, more than ever, it’s critical to harness predictive, well characterised preclinical models to bridge the translational gap into the clinic.

As part of the trusted Tumour Model series, Tumour Models London is back to support Pharma, Biotech, and Academic Institutions to best translate next generation In Vitro and In Vivo preclinical learnings to the clinic. As 2017 comes to a close, join the most trusted and assured meeting dedicated to help you predict the clinical outcome of your drug candidates more accurately in 2018.

Download the full programme to see how we can help you predict the clinical outcome of your drug candidates more accurately.

tn updated

 


PROUD TO PARTNER WITH:

 

 crownbio-logo  Jackson Laborartory

Lead Partner

Programme Partner

 champions oncology  nanostring

Programme Partner

Programme Partner

 Imprimer  Miltenyi_Biotec_logo

Spotlight Partner

Spotlight Partner

repositive-web-644x498

Mitra

Spotlight Partner

Exhibitor

AAEAAQAAAAAAAAj8AAAAJGFkM2Q5NDkwLTZhOTQtNDE4Yi05NjExLTdlMTU1MmNlM2VkNw

Exhibitor

OFFICIAL MEDIA PARTNERS

Print  CRISPR Congress - LabioTech

 


PART OF TUMOR MODELS SERIES

Tumor models SF logo   Tumor Models Boston Logo no year